By regulating BAP1-dependent transcriptional signatures, such as ASCL1/MYCL/E2F signaling, our studies highlight the potential to target BAP1’s activity using our next-generation iBAP inhibitor as a novel form of SCLC therapy (Fig. 4I). The gene discussed is ASCL1; the disease is small cell lung carcinoma.